Speaking this week at BIO CEO, the heads of Septerna, Upstream Bio and Actuate Therapeutics shared lessons from going public ...

TORONTO, Feb. 14, 2025 (GLOBE NEWSWIRE) -- Edesa Biotech, Inc. (Nasdaq:EDSA), a clinical-stage biopharmaceutical company ...

China has put Illumina on its ‘unreliable entity list’ after the US imposed sanctions on Beijing Genomics Institute, also a ...

Brent Sabatini, the Senior Vice President and Chief Accounting Officer at Vir Biotechnology, Inc. (NASDAQ:VIR), recently sold 1,562 shares of the company's common stock. According to InvestingPro data ...

A STAT examination shows how AI-powered biotechs like Absci and Generate Biomedicines routinely aggrandize their AI ...

All high schools, including Elliot Alternative, offer the design, visual and media arts pathway. Davis, Downey, Gregori and ...

EVENTS DURING THE FOURTH QUARTEREuropean Patent Office granted Active Biotech's patent application for eye drop formulation of laquinimod (October 23)Active Biotech's clinical trial of tasquinimod in ...

Vistagen Therapeutics, Inc.'s fasedienol shows promise in treating social anxiety; new results expected 2025. Click for my ...

JMP Securities reaffirmed their market outperform rating on shares of Enanta Pharmaceuticals (NASDAQ:ENTA – Free Report) in a report released on Tuesday,Benzinga reports. JMP Securities currently has ...

Eran Ovadya, Chief Financial Officer of NurExone stated, “The ISCT 2025 conference is a key opportunity to showcase our advances and to expand our U.S. presence. As we grow Exo-Top and pursue U.S.

Investment analysts at HC Wainwright dropped their Q2 2025 earnings estimates for Enanta Pharmaceuticals in a report released on Tuesday, February 11th. HC Wainwright analyst E. Arce now expects that ...